好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Expediting Autism Spectrum Disorder Diagnoses Through 好色先生, Training, and EMR-integration of the Childhood Autism Rating Scale (CARS-2) Diagnostic Tool
Child Neurology and Developmental Neurology
P1 - Poster Session 1 (8:00 AM-9:00 AM)
8-008

To increase formal autism spectrum disorder (ASD) diagnoses within a pediatric neurology division in a large southern academic medical center.
Early initiation of Applied Behavioral Analysis (ABA) therapy for children with ASD can improve outcomes. However, in the United States, the average age for ASD diagnosis is between 3.8-4.4 years. The American Academy of Pediatrics (AAP) recommends ASD-specific screening at 18 and 24 months. A positive screen should prompt a referral to a specialist for comprehensive evaluation and diagnosis. However, most insurance companies do not cover ABA therapy without a formal diagnosis. This, coupled with limited access to diagnostic tools and lack of confidence in post-diagnosis management, can result in unnecessary subspecialty referrals, further delaying diagnosis and treatment.

Using semi-structured interviews and surveys, we performed a needs assessment to evaluate local pediatric neurologists’ experiences with, and barriers to, making, disclosing, and counseling on formal ASD diagnoses; recommending therapeutic interventions; and providing secondary diagnostic referrals. We further designed and implemented a multi-modal educational curriculum that reviewed ASD diagnostic criteria, readily available diagnostic tools, billing for developmental testing, post-diagnosis counseling, and therapy referral procedures. Finally, applying informatics, design, and implementation research principles, we integrated the Childhood Autism Rating Scale-2 (CARS-2) into our electronic medical record (EMR) and optimized provider workflow to facilitate necessary documentation to improve overall diagnostic efficiency.
Primary outcomes examined the extent of CARS-2 utilization, frequency of ASD diagnosis, and changes in secondary referral patterns to other subspecialty providers.
Our quality improvement work provides a framework to empower providers with the necessary knowledge and skills to formally diagnose, counsel, and manage patients with a clear ASD diagnosis. 好色先生, training, and EMR integration of the CARS-2 diagnostic tool can narrow the quality care gap by making ASD diagnosis and management more timely, efficient, equitable, and patient-centered.
Authors/Disclosures
Mikael Guzman Karlsson, MD, PhD (Baylor College of Medince/Texas Children;'s Hospital)
PRESENTER 		An immediate family member of Dr. Guzman Karlsson has received personal compensation for serving as an employee of Thea Pharma, Inc..
Douglas A. Wells, Jr., MD (Baylor College of Medicine) Dr. Wells has nothing to disclose.
Christina Massrey, MD (Baylor College of Medicine) Dr. Massrey has nothing to disclose.
Maegan Newell, MD Dr. Newell has nothing to disclose.
Steven M. Lazar, MD (Texas Children's Neurology) Dr. Lazar has nothing to disclose.
Hasham Dhakwala No disclosure on file
Ramtin Kohandel No disclosure on file
Sreya Rahman (Baylor College of Medicine) No disclosure on file
Morgan Motakef No disclosure on file
Ameya S. Walimbe, MD, PhD (Ameya Walimbe) Dr. Walimbe has nothing to disclose.
Abhijit R. Das, MD (Baylor college of medicine) Dr. Das has nothing to disclose.
Melissa Mizerik, DO Dr. Mizerik has nothing to disclose.
Rima El Atrache, MD (Baylor College of Medicine) Dr. El Atrache has nothing to disclose.
Paisley L. Pauli, DO (Baylor College of Medicine) Ms. Pauli has nothing to disclose.
Jesse Levine, MD, PhD Dr. Levine has nothing to disclose.
Jamie Solis, MD Dr. Solis has nothing to disclose.
Lin Yao, MD, PhD (Texas Children's Hospital Baylor Medical School) Dr. Yao has nothing to disclose.
Lisa T. Emrick, MD (Department of Neurology & Developmental Neuroscience) Dr. Emrick has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Arkema. The institution of Dr. Emrick has received research support from Lysogene. The institution of Dr. Emrick has received research support from PTC. The institution of Dr. Emrick has received research support from Roche. The institution of Dr. Emrick has received research support from NIH.
Sarah R. Risen, MD Dr. Risen has nothing to disclose.
Kristen Fisher, DO (Baylor College of Medicine) Dr. Fisher has nothing to disclose.
Shannon M. DiCarlo, MD, FAAN Dr. DiCarlo has nothing to disclose.